Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Lapatinib With or Without Cixutumumab in HER2+ Breast Cancer
NCT00684983Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2008
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in breast cancer, sponsored by National Cancer Institute. Started Jul 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00684983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684983.